Allogene Therapeutics Inc (NAS:ALLO)
$ 2.02 -0.12 (-5.61%) Market Cap: 448.70 Mil Enterprise Value: 252.75 Mil PE Ratio: 0 PB Ratio: 0.91 GF Score: 36/100

Allogene Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 11:45PM GMT
Release Date Price: $6.09 (+2.70%)
Lut Ming Cheng
JPMorgan Chase & Co, Research Division - Research Analyst

Good afternoon, everyone. Thank you for joining us for another session at the 41st Annual JPMorgan Healthcare Conference. My name is Brian Cheng. I'm one of the senior biotech analysts here at the firm. Presenting next is Allogene. With us today, we have President and CEO of Allogene, David Chang.

I'll turn over the stage to David, and then the presentation will be followed by a Q&A session.

David D. Chang
Allogene Therapeutics, Inc. - Co-Founder, President, CEO & Director

Thank you, Brian, for hosting us, and thank you for those who are in the audience. So I will be making some forward-looking statements, which will be subject to the disclosures we have in the SEC filing.

So Allogene is really here to democratize the cell therapy and our mission is for the patients. And we have 6 foundational platforms from AlloCAR T, TurboCAR T, Cloak & Dagger, manufacturing as well as iPSC programs to fuel the innovation. Also, we distinguish ourselves by having

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot